NBIX
Neurocrine Biosciences Inc
143.50$
-1.4%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 42.5% | 24.0% | 25.3% | 10.9% | 25.4% | 38.6% | 11.3% | 14.8% | 28.6% | 48.2% | 17.9% | 14.2% | 26.6% | |
| 1.1% | 1.1% | 1.2% | 1.2% | 1.0% | 1.1% | 1.3% | 1.1% | 1.0% | 0.9% | 0.9% | 2.6% | 1.4% | |
| 9.6% | 7.4% | 8.6% | 7.3% | 6.7% | 10.6% | 9.2% | 7.7% | 6.8% | 7.3% | 7.0% | 6.8% | 7.0% | |
| 9.2% | -10.4% | -6.1% | -14.6% | 0.7% | 15.0% | -4.1% | -5.7% | -23.3% | 14.8% | -0.4% | -8.4% | -4.4% | |
| 1.5% | 1.0% | 2.2% | 2.0% | 1.3% | 1.2% | 1.9% | 1.8% | 1.7% | 0.3% | 1.1% | 0.8% | 1.0% | |
| -19.5% | -39.2% | -10.7% | -4.8% | 4.0% | -10.9% | 2.5% | -4.2% | -24.7% | -6.6% | -62.1% | -14.1% | -26.4% | |
| – | – | 0.0% | 0.0% | – | -47.8% | -26.2% | -2.6% | 0.0% | 0.0% | -6.6% | -1.3% | -2.0% | |
| – | – | – | – | 0.0% | 0.0% | – | – | 0.0% | 0.0% | – | – | – | |
| 3.8% | 6.9% | 13.6% | -49.6% | 4.2% | -46.2% | -20.6% | -0.5% | 5.7% | 4.6% | -10.6% | 6.6% | 1.8% | |
| 26.8% | -8.3% | 28.2% | -43.5% | 33.7% | -18.5% | -6.8% | 10.2% | 9.6% | 46.3% | -54.8% | 6.7% | 2.0% | |
| 41.0% | 22.9% | 23.1% | 9.0% | 24.1% | 37.5% | 9.4% | 13.0% | 27.0% | 48.5% | 16.8% | 13.4% | 25.8% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.